These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 8202100)

  • 1. Sotalol.
    Hohnloser SH; Woosley RL
    N Engl J Med; 1994 Jul; 331(1):31-8. PubMed ID: 8202100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiarrhythmic actions of DL-sotalol in ventricular and supraventricular arrhythmias.
    Singh BN
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S75-90. PubMed ID: 1279313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with sotalol in the treatment of cardiac arrhythmias.
    Kirschenbaum HL; Rosenberg JM
    Clin Ther; 1994; 16(3):346-64. PubMed ID: 7923303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sotalol hydrochloride (Betapace): a new antiarrhythmic drug.
    Dunnington CS
    Am J Crit Care; 1993 Sep; 2(5):397-406. PubMed ID: 8220672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophysiological mechanisms of action of the levorotatory isomer of sotalol in a canine infarct model of inducible ventricular tachycardia: comparison with the beta-1 receptor antagonist bisoprolol.
    Aidonidis I; Rizos I; Hilbel T; Kuebler W; Brachmann J
    J Mol Cell Cardiol; 1994 Jul; 26(7):841-8. PubMed ID: 7966352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes.
    Chézalviel-Guilbert F; Davy JM; Poirier JM; Weissenburger J
    J Am Coll Cardiol; 1995 Sep; 26(3):787-92. PubMed ID: 7642874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of dispersion of repolarization and prolongation of postrepolarization refractoriness explain the antiarrhythmic effects of quinidine in a model of short QT syndrome.
    Milberg P; Tegelkamp R; Osada N; Schimpf R; Wolpert C; Breithardt G; Borggrefe M; Eckardt L
    J Cardiovasc Electrophysiol; 2007 Jun; 18(6):658-64. PubMed ID: 17521304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the long-term effects of sotalol and atenolol on QT interval and arrhythmias after myocardial infarction.
    Cobbe SM; Alexopoulos D; Winner SJ; McCaie CP; Cobbe PC; Johnston J
    Eur Heart J; 1988 Jan; 9(1):24-31. PubMed ID: 2450026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sotalol: An important new antiarrhythmic.
    Anderson JL; Prystowsky EN
    Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sotalol: a novel beta-blocker with class III anti-arrhythmic activity.
    Leibowitz D
    J Clin Pharmacol; 1993 Jun; 33(6):508-12. PubMed ID: 8366175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sotalol: a breakthrough antiarrhythmic?
    Nappi JM; McCollam PL
    Ann Pharmacother; 1993 Nov; 27(11):1359-68. PubMed ID: 8286812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced torsade de pointes.
    Raehl CL; Patel AK; LeRoy M
    Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia.
    Saul JP; Ross B; Schaffer MS; Beerman L; Melikian AP; Shi J; Williams J; Barbey JT; Jin J; Hinderling PH;
    Clin Pharmacol Ther; 2001 Mar; 69(3):145-57. PubMed ID: 11240979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotalol: a new agent for the treatment of ventricular arrhythmias.
    Samoil D; Grubb BP; Temesy-Armos PN
    Am J Med Sci; 1994 Jan; 307(1):49-53. PubMed ID: 8291508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sotalol: a new class III antiarrhythmic agent.
    Zanetti LA
    Clin Pharm; 1993 Dec; 12(12):883-91. PubMed ID: 8137605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.
    Mason JW
    N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
    Scholz H
    Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation.
    Campbell RW; Furniss SS
    Am J Cardiol; 1993 Aug; 72(4):80A-85A. PubMed ID: 8346732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
    Fitton A; Sorkin EM
    Drugs; 1993 Oct; 46(4):678-719. PubMed ID: 7506652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.